

Singular Health Group Ltd: SHG

2 August 2022

ASX Compliance Pty Ltd
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

Announcement regarding collaboration with Osteopore Ltd (ASX: OSX)

Singular Health Group (ASX: SHG) (Singular or the Company) provides the following responses to clarify recent disclosures regarding its collaboration with Osteopore Ltd (ASX: OSX) as announced on 1 August 2022.

The Company has signed a collaboration agreement with Osteopore Ltd. The agreement is effective from 1 August 2022, and shall continue for a period of three (3) years unless earlier terminated in accordance with the terms of the agreement, or extended by either the Company or Osteopore Ltd.

The aim of the agreement is to continue and expand the formal collaboration between both parties to improve the accuracy of patient specific implant design and revolutionise surgeon experience for pre-surgical planning.

Such collaboration includes investigating and identifying potential business and technology opportunities including but not limited to:

- Assessing potential merger and acquisition targets that would be value-accretive to both or each company;
- Forming joint research and development proposals for new applications for each-others' technology and service offerings; and
- Investigating various business opportunities for both Singular Health Group and Osteopore in the USA and Australia

The agreement also includes a project plan for AI Powered Implant Design and Virtual Reality Planning for Surgery:

- Osteopore will initially license four (4) 3Dicom R&D suite licences from Singular and introduce its surgeons to this platform. When surgeons interact on this platform, it will have a landing page which indicates that the design is provided by Osteopore. These 4 licences will be purchased and used for a period of eighteen (18) months from the effective date of the agreement. From time to time, upgrades to the 3Dicom software may be required. Under the terms of the agreement, Osteopore has the right to automatically receive these upgrades without additional fees, and Osteopore will be provided such upgrades for a period of three (3) years from the effective date of the agreement.
- Singular will undertake the technical task of designing the additional algorithm for the cranial implant skirt (with the IP belonging to Singular). Osteopore shall have an exclusive period of three (3) years from the date of delivery of this AI cranial implant within the skirt by Singular to Osteopore, to use this component of the AI cranial implant skirting, and that Osteopore shall be provided without additional costs, three (3) years of upgrades that occur for this component.

- The parties agree that notwithstanding the above, Singular will in due course seek certification of the above products and shall provide the certified versions to Osteopore if certified during the respective 3-year exclusive periods referred to above.

Each party will make its own contributions in terms of manpower, equipment, facilities, cash funding and other contributions to advance the achievements of the agreement described above, or as agreed from time to time by all parties in writing. The costs of the enterprise licences for the 3Dicom R&D and VSP software as well as the development of Skirted AI Cranial Implant Model are not expected to be material at this stage to either party.

Either party shall be entitled to terminate the agreement immediately by notice in writing to the terminated party if any of the below events occur. The events are:

- If the terminated party commits any material breach of any of its obligations under the agreement and shall fail to remedy such breach within thirty (30) days after being given notice by the terminating party to do so; or
- If the terminated party shall go into liquidation, whether compulsory or voluntary (except for the purposes of a bona fide reconstruction or amalgamation with the consent of all other parties, such consent not to be unreasonably withheld) or if the terminated party shall have an administrator appointed or if a receiver, administrative receiver or manager shall be appointed over any part of its asset or undertaking.

Authorised for ASX release by the Managing Director.

Ends

For further information contact

Investors	Corporate	Media
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary sw@grangeconsulting.com.au	Julia Maguire The Capital Network julia@thecapitalnetwork.com.au

About Singular Health:

Singular Health Group Limited (ASX:SHG) is a medical technology company that empowers practitioners and patients via personalised surgical planning solutions that drive better health outcomes.

Singular Health has developed a proprietary Volumetric Rendering Platform (VRP) that leverages existing 2D radiological images to generate fully immersive patient-specific 3D/VR models. Although Singular Health's VRP technology is applicable to other sectors in which the visualisation of dynamic data is crucial, with it already being utilised in the mining sector, the Company's core focus is on the medical sector.

Complementing its VRP technology, Singular Health has acquired Virtual Surgical Planning software and a 25% stake in medical-grade 3D printing company Additive Engineering. These investments represent key milestones in Singular Health's efforts to commercialise its 'Scan to Surgery' initiative, a world-first vertically integrated platform that revolutionises the planning and execution of personalised surgical procedures.

A successful full-scale commercialisation of this end-to-end personalised surgical planning platform will give Singular Health the capability to penetrate a multi-billion-dollar global market opportunity in the medical visualisation and additive manufacturing spaces.

With Singular Health, practitioners are empowered by having the ability to collaborate with producers of patient-specific medical components in real-time while patients benefit from having access to easily comprehensible and enhanced medical information.

To learn more, please visit: www.singular.health

About Osteopore Limited:

Osteopore Ltd, an Australian ASX listed company (ASX: OSX) with R&D and manufacturing in Singapore, is the global leader in the manufacture of innovative regenerative implants at commercial scale. By combining biomimetic tissue science with proprietary 3D printing and materials technology, Osteopore produces medical implants to meet the needs of both tissue and bone reconstruction as well as restoration. These bioresorbable implants provide a scaffold for bone regeneration, dissolving predictably over time to leave only natural bone tissue. In collaboration with clinicians and researchers, Osteopore develops and manufactures implants that address unmet clinical needs which improve patient outcomes, enhances lives, and potentially reduces healthcare costs.

For more information, visit us at www.osteopore.com